PMID- 26658664
DCOM- 20160411
LR  - 20151215
IS  - 1532-0979 (Electronic)
IS  - 0147-5185 (Linking)
VI  - 40
IP  - 1
DP  - 2016 Jan
TI  - Primary Cutaneous Follicle Center Lymphomas Expressing BCL2 Protein Frequently
      Harbor BCL2 Gene Break and May Present 1p36 Deletion: A Study of 20 Cases.
PG  - 127-36
LID - 10.1097/PAS.0000000000000567 [doi]
AB  - The classification of cutaneous follicular lymphoma (CFL) into primary cutaneous 
      follicle center lymphoma (PCFCL) or secondary cutaneous follicular lymphoma
      (SCFL) is challenging. SCFL is suspected when tumor cells express BCL2 protein,
      reflecting a BCL2 translocation. However, BCL2 expression is difficult to assess 
      in CFLs because of numerous BCL2+ reactive T cells. To investigate these issues
      and to further characterize PCFCL, we studied a series of 25 CFLs without any
      extracutaneous disease at diagnosis, selected on the basis of BCL2 protein
      expression using 2 BCL2 antibodies (clones 124 and E17) and BOB1/BCL2 double
      immunostaining. All cases were studied using interphase fluorescence in situ
      hybridization with BCL2, BCL6, IGH, IGK, IGL breakapart, IGH-BCL2 fusion, and
      1p36/1q25 dual-color probes. Nineteen CFLs were BCL2 positive, and 6 were
      negative. After a medium follow-up of 24 (6 to 96) months, 5 cases were
      reclassified as SCFL and were excluded from a part of our analyses. Among BCL2+
      PCFCLs, 60% (9/15) demonstrated a BCL2 break. BCL2-break-positive cases had a
      tendency to occur in the head and neck and showed the classical phenotype of
      nodal follicular lymphoma (CD10+, BCL6+, BCL2+, STMN+) compared with
      BCL2-break-negative PCFCLs. Del 1p36 was observed in 1 PCFCL. No significant
      clinical differences were observed between BCL2+ or BCL2- PCFCL. In conclusion,
      we show that a subset of PCFCLs harbor similar genetic alterations, as observed
      in nodal follicular lymphomas, including BCL2 breaks and 1p36 deletion. As BCL2
      protein expression is usually associated with the presence of a BCL2
      translocation, fluorescence in situ hybridization should be performed to confirm 
      this hypothesis.
FAU - Szablewski, Vanessa
AU  - Szablewski V
AD  - *Pathology Department, CHU Montpellier, Gui de Chauliac Hospital, Montpellier
      daggerDermatology Department section signImmunology and Hematology Department
      paragraph signPathology Department, AP-HP, Groupe Henri Mondor-Albert Chenevier
      double daggerINSERM, U955 team 9 parallelMedical University, Paris Est Creteil
      university (UPEC), UMR-S, Creteil, France.
FAU - Ingen-Housz-Oro, Saskia
AU  - Ingen-Housz-Oro S
FAU - Baia, Maryse
AU  - Baia M
FAU - Delfau-Larue, Marie-Helene
AU  - Delfau-Larue MH
FAU - Copie-Bergman, Christiane
AU  - Copie-Bergman C
FAU - Ortonne, Nicolas
AU  - Ortonne N
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Surg Pathol
JT  - The American journal of surgical pathology
JID - 7707904
RN  - 0 (BCL2 protein, human)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/analysis/*genetics
MH  - *Chromosome Deletion
MH  - *Chromosomes, Human, Pair 1
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Female
MH  - *Gene Rearrangement
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphoma, Follicular/chemistry/*genetics/pathology/therapy
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - Proto-Oncogene Proteins c-bcl-2/analysis/*genetics
MH  - Skin Neoplasms/chemistry/*genetics/pathology/therapy
MH  - Time Factors
MH  - *Translocation, Genetic
MH  - Treatment Outcome
EDAT- 2015/12/15 06:00
MHDA- 2016/04/12 06:00
CRDT- 2015/12/15 06:00
PHST- 2015/12/15 06:00 [entrez]
PHST- 2015/12/15 06:00 [pubmed]
PHST- 2016/04/12 06:00 [medline]
AID - 10.1097/PAS.0000000000000567 [doi]
AID - 00000478-201601000-00016 [pii]
PST - ppublish
SO  - Am J Surg Pathol. 2016 Jan;40(1):127-36. doi: 10.1097/PAS.0000000000000567.